Holen Sie sich die Stockscreener-App
14.20
0.25%
-0.03
Schlusskurs vom Vortag:
$14.23
Offen:
$14.09
24-Stunden-Volumen:
329.22K
Relative Volume:
0.37
Marktkapitalisierung:
$1.49B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-9.1802
EPS:
-1.5468
Netto-Cashflow:
$-104.72M
1W Leistung:
-2.97%
1M Leistung:
+8.28%
6M Leistung:
-49.34%
1J Leistung:
-16.65%
1-Tages-Spanne:
$14.08
$14.79
1-Wochen-Bereich:
$13.78
$15.33
52-Wochen-Spanne:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.20 | 1.47B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.68 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.92 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
388.58 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.04 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.80 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - PR Newswire
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by Analysts at Raymond James Financial - MarketBeat
Heatmap analysis for Edgewise Therapeutics Inc. and competitorsSmart Stock Forecast Using AI Algorithms - Newser
Is Edgewise Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Sector Based Breakout Stock Forecast - Newser
How Edgewise Therapeutics Inc. stock performs during market volatilitySector Rotation Strategy for Smart Traders - Newser
Published on: 2025-07-31 00:37:16 - Newser
Visualizing Edgewise Therapeutics Inc. stock with heatmapsFree Low Risk Swing Trade Opportunity List - Newser
How sentiment analysis helps forecast Edgewise Therapeutics Inc.Free Weekly Top Gainers Forecast Watchlist - Newser
Raymond James Initiates Edgewise Therapeutics at Strong Buy - MarketScreener
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
37,591 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Skandinaviska Enskilda Banken AB publ - MarketBeat
When is the best time to buy Edgewise Therapeutics Inc. stockEarnings Report Summary with Market Impact - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplySector Rotation Outlook With Historical Summary - Newser
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating By Investing.com - Investing.com Canada
Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating - Investing.com
Edgewise Therapeutics, Inc. (EWTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Edgewise Therapeutics Inc. stock attracts strong analyst attentionReal-Time Setup Summary with ROI Focus - Newser
How Interest Rate Changes Impact Edgewise Therapeutics Inc. Stock PerformanceWeekly Portfolio Update with ROI Focus - Newser
Edgewise Therapeutics Inc. Could See a Relief Rally From SupportChart Breakout Buy Signal Detection Confirmed - beatles.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Edgewise Therapeutics, Inc. (EWTX) And Encourages Investors to Connect - ACCESS Newswire
Why is Edgewise Therapeutics Inc. stock attracting strong analyst attentionCapital growth strategies that work - jammulinksnews.com
What is the dividend policy of Edgewise Therapeutics Inc. stockMarket-leading growth rates - jammulinksnews.com
What catalysts could drive Edgewise Therapeutics Inc. stock higher in 2025Game-changing returns - jammulinksnews.com
What are the latest earnings results for Edgewise Therapeutics Inc.Breakthrough profit margins - jammulinksnews.com
What are the technical indicators suggesting about Edgewise Therapeutics Inc.Invest confidently with professional market insights - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Edgewise Therapeutics, Inc. (EWTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
What are Edgewise Therapeutics Inc. company’s key revenue driversDiscover stocks with massive upside potential - jammulinksnews.com
Sectors Driving Future Growth for Edgewise Therapeutics Inc. StockFree Access to Group - Newser
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug - MSN
Edgewise Therapeutics, Inc. (EWTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What analysts say about Edgewise Therapeutics Inc. stockRapidly growing investment returns - PrintWeekIndia
Jennison Associates LLC Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Readystate Asset Management LP Boosts Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
What drives Edgewise Therapeutics Inc. stock priceRapid wealth accumulation - Autocar Professional
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Edgewise Therapeutics, Inc. (EWTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Edgewise Therapeutics Inc. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
Becker Muscular Dystrophy Pipeline 2025: Key Companies, MOA, - openPR.com
BlackRock, Inc. Reduces Stake in Edgewise Therapeutics Inc. - GuruFocus
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Arizona State Retirement System - Defense World
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
May 02 '25 |
Sale |
16.45 |
1,551 |
25,520 |
18,521 |
| MOORE JOHN R | General Counsel |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
8,461 |
| MOORE JOHN R | General Counsel |
May 02 '25 |
Sale |
16.45 |
1,930 |
31,757 |
6,531 |
| KOCH KEVIN | President and CEO |
May 01 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
24,895 |
| KOCH KEVIN | President and CEO |
May 02 '25 |
Sale |
16.45 |
4,276 |
70,358 |
20,619 |
| Donovan Joanne M. | CMO |
May 01 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
26,775 |
| Donovan Joanne M. | CMO |
May 02 '25 |
Sale |
16.45 |
5,187 |
85,348 |
21,588 |
| Derakhshan Behrad | Chief Business Officer |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
22,046 |
| Derakhshan Behrad | Chief Business Officer |
May 02 '25 |
Sale |
16.45 |
1,691 |
27,824 |
20,355 |
| Carruthers R Michael | Chief Financial Officer |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
82,328 |
3.57%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):